Howard Danny R (69 results)

Pictorial Illustrated Cover. Condition: Near Fine. First Edition By This Publisher. 100 pages including covers; Published by Marvel Comics Group, New York, NY, USA, 1988; 1st Printing; Softcover, Trade Paperback, Graphic Novel; 330 Grams; As the Red Terror, a bizarre, magical dark force whose victims disappear without a trace, descends upon Aquilonia, King Conan sets out to destroy its source, evil, conquest-hungry sorcerer-priests from across the sea; This book was written as the definite end to the saga of Conan. In his mid-sixties, longtime king of Aquilonia, his beloved wife having died and his son now an adult, Conan has become weary of his now dull existence as a monarch. ROY THOMAS Adaption of the L. Sprague de Camp and Lin Cater story (based characters created by Robert E. Howard); Doug Beekman painted cover; Art by; John Buscema, Danny Bulandi, Ricado Villamonte, Armando Gil and Dave Simons; Light Scuffing to cover; Moderate Rubbing Wear to back cover, Size: 4to - over 9¾" - 12" tall. Doug Beekman painted cover; Art by; John Buscema, Danny Bulandi, Ricado Villamonte, Armando Gil and Dave Simons; (illustrator). Book.…

Softcover. Condition: Very Good. First Edition; First Printing. Very Good paperback with minor cover edgewear. Contributors other than the editors listed on the contents page: Charles F. Buddy, Daniel O'Donovan, John Power, Maxine Whiteside, Oliver Jaynes, George Wheeler, Eddie Welch, Jimmy Durante, Hildy Crawford, Harry Oliver, Mousie Powell, Danny Thomas, Percy Whiteside. Unpaginated. [dp50 1210]. ; Shlf [Ntsp]; 8vo 8" - 9" tall; Unpaginated pages. …

hardcover. Condition: Good. Most items will be dispatched the same or the next working day. A copy that has been read but remains in clean condition. All of the pages are intact and the cover is intact and the spine may show signs of wear. The book may have minor markings which are not specifically mentioned. Ex library copy with usual stamps & stickers.…

Condition: New. A brand new book in pristine condition. Showing zero signs of shelf wear, creases, or damage.

Condition: Sehr gut. Zustand: Sehr gut | Seiten: 344 | Sprache: Englisch | Produktart: Bücher | In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely ¿ to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist¿s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.…

Condition: New.

Hardcover. Condition: New. In shrink wrap. Looks like an interesting title.

Condition: New.

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Condition: gut. 2005. Pharmacokinetics in Drug Development: Regulatory and Development Paradigms (Volume 2). (Biotechnology: Pharmaceutical Aspects) In englischer Sprache. pages.

Condition: New. In English.

Condition: New. In English.

Condition: New.

Condition: New.

Taschenbuch. Condition: Neu. Pharmacokinetics in Drug Development | Problems and Challenges in Oncology, Volume 4 | Peter L. Bonate (u. a.) | Taschenbuch | xii | Englisch | 2018 | Springer | EAN 9783319818054 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.…

Condition: New.

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely - to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist's point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. …

Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely - to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist's point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.…

Condition: New. In English.

Condition: New. In English.

Condition: New. In English.

Condition: New. A guide to pharmacokinetics (PK) and its role in drug development. Suitable for graduate level students and scientists in the areas of clinical pharmacology and PK, it intends to fill a gap between the academic science and the practical application of that knowledge in drug development. Editor(s): Bonate, Peter L.; Howard, Danny R. Num Pages: 640 pages, 74 black & white tables, biography. BIC Classification: MMG. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 34. Weight in Grams: 1324. . 2005. Hardback. . . . .…

Condition: Sehr gut. Zustand: Sehr gut | Seiten: 332 | Sprache: Englisch | Produktart: Bücher | The topics chosen for this volume were selected because they are some of the current development or technological issues facing drug development project teams.  They regard the practical considerations for assessment of selected special development populations.  For example, they include characterization of drug disposition in pregnant subjects, for measuring arrhythmic potential, for analysis tumor growth modeling, and for disease progression modeling.  Practical considerations for metabolite safety testing, transporter assessments, Phase 0 testing, and development and execution of drug interaction programs reflect current regulatory topics meant to address enhancement of both safety assessment and early decision-making during new candidate selection.  Important technologies like whole body autoradiography, digital imaging and dried blood spot sample collection methods are introduced, as both have begun to take a more visible role in pharmacokinetic departments throughout the industry.…

Condition: New. pp. 310.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - The topics chosen for this volume were selected because they are some of the current development or technological issues facing drug development project teams. They regard the practical considerations for assessment of selected special development populations. For example, they include characterization of drug disposition in pregnant subjects, for measuring arrhythmic potential, for analysis tumor growth modeling, and for disease progression modeling. Practical considerations for metabolite safety testing, transporter assessments, Phase 0 testing, and development and execution of drug interaction programs reflect current regulatory topics meant to address enhancement of both safety assessment and early decision-making during new candidate selection. Important technologies like whole body autoradiography, digital imaging and dried blood spot sample collection methods are introduced, as both have begun to take a more visible role in pharmacokinetic departments throughout the industry.…

Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - The topics chosen for this volume were selected because they are some of the current development or technological issues facing drug development project teams. They regard the practical considerations for assessment of selected special development populations. For example, they include characterization of drug disposition in pregnant subjects, for measuring arrhythmic potential, for analysis tumor growth modeling, and for disease progression modeling. Practical considerations for metabolite safety testing, transporter assessments, Phase 0 testing, and development and execution of drug interaction programs reflect current regulatory topics meant to address enhancement of both safety assessment and early decision-making during new candidate selection. Important technologies like whole body autoradiography, digital imaging and dried blood spot sample collection methods are introduced, as both have begun to take a more visible role in pharmacokinetic departments throughout the industry.…